MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 204920 | Name: Bevonium methylsulfate

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Bevonium methylsulfate (CG-201), currently being developed by CG Therapeutics, Inc. is an injection that stimulates antibodies to block the pathological forms of hCG that help cancer cells grow and evade the immune system. According to CG Therapeutics's website, CG201 was originally created in collaboration with the World Health Organization as a low-cost contraceptive method for developing countries. CG201 is now approved for a Phase I clinical trial in Sweden. A single injection can protect against pregnancy for up to one year, and protection is reversible after that.

Chemical Structure

Bevonium methylsulfate
Bevonium methylsulfate
CAS#5205-82-3 (methylsulfate)

Theoretical Analysis

MedKoo Cat#: 204920

Name: Bevonium methylsulfate

CAS#: 5205-82-3 (methylsulfate)

Chemical Formula: C23H31NO7S

Exact Mass:

Molecular Weight: 465.56

Elemental Analysis: C, 59.34; H, 6.71; N, 3.01; O, 24.06; S, 6.89

Price and Availability

Size Price Availability Quantity
Bulk Inquiry
Buy Now
Add to Cart
Related CAS #
33371-53-8 (cation) 5205-82-3 (methylsulfate)
Synonym
CG201; CG 201; CG-201; Bevonium methylsulfate; Acabel; Piribenzil methosulfate; Piribenzil methyl sulfate; Bevonium metilsulfate.
IUPAC/Chemical Name
2-((2-hydroxy-2,2-diphenylacetoxy)methyl)-1,1-dimethylpiperidin-1-ium methyl sulfate.
InChi Key
AXKJGGRSAVLXTE-UHFFFAOYSA-M
InChi Code
InChI=1S/C22H28NO3.CH4O4S/c1-23(2)16-10-9-15-20(23)17-26-21(24)22(25,18-11-5-3-6-12-18)19-13-7-4-8-14-19;1-5-6(2,3)4/h3-8,11-14,20,25H,9-10,15-17H2,1-2H3;1H3,(H,2,3,4)/q+1;/p-1
SMILES Code
C[N+]1(C)C(COC(C(C2=CC=CC=C2)(O)C3=CC=CC=C3)=O)CCCC1.O=S(OC)([O-])=O
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO, not in water
Shelf Life
>5 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info
         

Preparing Stock Solutions

The following data is based on the product molecular weight 465.56 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Stall L, Lee J, McCullough M, Nsrouli-Maktabi H, Spies JB. Effectiveness of elective unilateral uterine artery embolization: a case-control study. J Vasc Interv Radiol. 2011 May;22(5):716-22. PubMed PMID: 21514525. 2: Hu NN, Kaw D, McCullough MF, Nsouli-Maktabi H, Spies JB. Menopause and menopausal symptoms after ovarian artery embolization: a comparison with uterine artery embolization controls. J Vasc Interv Radiol. 2011 May;22(5):710-715.e1. PubMed PMID: 21514524. 3: Costantino M, Lee J, McCullough M, Nsouli-Maktabi H, Spies JB. Bilateral versus unilateral femoral access for uterine artery embolization: results of a randomized comparative trial. J Vasc Interv Radiol. 2010 Jun;21(6):829-35; quiz 835. Epub 2010 Apr 15. Erratum in: J Vasc Interv Radiol. 2010 Nov;21(11):1786. Nsrouli-Maktabi, Hala [corrected to Nsouli-Maktabi, Hala]. PubMed PMID: 20399113. 4: Banovac F, Cheng P, Campos-Nanez E, Kallakury B, Popa T, Wilson E, Abeledo H, Cleary K. Radiofrequency ablation of lung tumors in swine assisted by a navigation device with preprocedural volumetric planning. J Vasc Interv Radiol. 2010 Jan;21(1):122-9. Epub 2009 Nov 25. PubMed PMID: 19939704; PubMed Central PMCID: PMC2818540. 5: Meyer J, Nsouli-Maktabi H, Spies JB. Quality of interventional radiology literature: a review of articles published in JVIR and CVIR. J Vasc Interv Radiol. 2009 Oct;20(10):1271-6. Epub 2009 Jul 23. Review. PubMed PMID: 19631559. 6: White AM, Banovac F, Yousefi S, Slack RS, Spies JB. Uterine fibroid embolization: the utility of aortography in detecting ovarian artery collateral supply. Radiology. 2007 Jul;244(1):291-8. PubMed PMID: 17581907. 7: White AM, Banovac F, Spies JB. Patient radiation exposure during uterine fibroid embolization and the dose attributable to aortography. J Vasc Interv Radiol. 2007 Apr;18(4):573-6. PubMed PMID: 17446550. 8: Spies JB, Cornell C, Worthington-Kirsch R, Lipman JC, Benenati JF. Long-term outcome from uterine fibroid embolization with tris-acryl gelatin microspheres: results of a multicenter study. J Vasc Interv Radiol. 2007 Feb;18(2):203-7. PubMed PMID: 17327552. 9: Yousefi S, Czeyda-Pommersheim F, White AM, Banovac F, Hahn WY, Spies JB. Repeat uterine artery embolization: indications and technical findings. J Vasc Interv Radiol. 2006 Dec;17(12):1923-9. PubMed PMID: 17185687. 10: Spies JB. Adding to our understanding of uterine fibroid embolization. AJR Am J Roentgenol. 2006 Mar;186(3):846-7. PubMed PMID: 16498119.